A previous observational study by Macías et al. [115] concluded that drug–drug interactions which contraindicates the use of LPV/r is often overlooked in the context of the ongoing COVID-19 healthcare crisis, signifying that physicians treating COVID-19 patients using LPV/r should be aware of potential interactions associated with CYP3A4 inhibition. This evidence concerns the gene CYP3A4 and COVID-19.